Filing Details

Accession Number:
0001209191-20-049578
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-03 21:47:52
Reporting Period:
2020-08-28
Accepted Time:
2020-09-03 21:47:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1339970 Atyr Pharma Inc LIFE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1219015 K John Clarke 3545 John Hopkins Court, Suite #250
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-08-28 100 $4.00 117,843 No 4 S Indirect See Footnote
Common Stock Disposition 2020-09-02 7,260 $4.01 110,583 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 7,492 Direct
Footnotes
  1. There shares are owned directly by CHP II, LLP ("CHP"). The general partner of CHP is CHP II Management, LLC, ("CHP Management"). The managing member of CHP Management, John Clarke, Brandon Hull and John Park, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by CHP. Each reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such reporting persons are the beneficial owners of such securities for Section 16 or any other purpose.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.